157 related articles for article (PubMed ID: 15823760)
1. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
Tripathy D; Body JJ; Bergström B
Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
4. Ibandronate reduces skeletal morbidity in patients with breast cancer.
Tripathy A D; Diel I; Body JJ
Semin Oncol; 2004 Oct; 31(5 Suppl 10):64-6. PubMed ID: 15490378
[TBL] [Abstract][Full Text] [Related]
5. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
Body JJ; Diel IJ; Lichinitzer M; Lazarev A; Pecherstorfer M; Bell R; Tripathy D; Bergstrom B
Br J Cancer; 2004 Mar; 90(6):1133-7. PubMed ID: 15026791
[TBL] [Abstract][Full Text] [Related]
6. Ibandronate: its role in metastatic breast cancer.
Cameron D; Fallon M; Diel I
Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Gordon DH
Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
[TBL] [Abstract][Full Text] [Related]
9. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
Tripathy D; Lichinitzer M; Lazarev A; MacLachlan SA; Apffelstaedt J; Budde M; Bergstrom B;
Ann Oncol; 2004 May; 15(5):743-50. PubMed ID: 15111341
[TBL] [Abstract][Full Text] [Related]
10. Ibandronate: efficacy in the treatment of metastatic bone disease.
Diel IJ
Future Oncol; 2005 Oct; 1(5):593-607. PubMed ID: 16556036
[TBL] [Abstract][Full Text] [Related]
11. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
Pecherstorfer M; Diel IJ
Support Care Cancer; 2004 Dec; 12(12):877-81. PubMed ID: 15372222
[TBL] [Abstract][Full Text] [Related]
12. Ibandronate in metastatic bone pain.
Heidenreich A; Ohlmann C; Body JJ
Semin Oncol; 2004 Oct; 31(5 Suppl 10):67-72. PubMed ID: 15490379
[TBL] [Abstract][Full Text] [Related]
13. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
15. [The role of ibandronate in the daily oncological practice].
Nagykálnai T
Magy Onkol; 2006; 50(4):325-7. PubMed ID: 17216006
[TBL] [Abstract][Full Text] [Related]
16. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.
Heras P; Karagiannis S; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2007 Nov; 16(6):539-42. PubMed ID: 17944770
[TBL] [Abstract][Full Text] [Related]
17. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
[TBL] [Abstract][Full Text] [Related]
19. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
Diel IJ; Body JJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
[TBL] [Abstract][Full Text] [Related]
20. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
Meattini I; Bruni A; Scotti V; Livi L; De Luca Cardillo C; Galardi A; Cipressi S; Biti G
J Chemother; 2010 Feb; 22(1):58-62. PubMed ID: 20227995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
